July 30, 2013 -- Pfizer has unveiled plans to internally carve up its business into three different sections, in a move designed maximise the value of its entire portfolio. The drug giant said that from January next year, it will house two separate 'innovative' business units and a ' value' one, with each operating in both emerging and established markets.
One of these innovative business units will include products across multiple therapeutic areas expected to have market exclusivity beyond 2015, and will be led by Geno Germano, Group President, Innovative Products Group.
The other will include Vaccines, Oncology and Consumer Healthcare, and will be under the direction of Amy Schulman, Group President, Vaccines, Oncology and Consumer Healthcare.
Read the rest of the article here.